Methods
Searches for studies were performed in peer-reviewed and gray
literature. The following elements were used to define eligibility
criteria: (1) Population, individuals with laboratory-confirmed
SARS-CoV-2 infection; (2) Intervention, nitazoxanide; (3) Comparison,
placebo; (4) Outcomes: positive RT-PCR status, composite measure of
disease progression (severe COVID-19, ICU admission or invasive
mechanical ventilation), death, serum biomarkers of inflammation
(C-reactive protein, IL-6, and IL-8), and any adverse events; (5) Study
type: blinded, placebo-controlled, randomized clinical trials (RCT).
Treatment effects were reported as relative risk (RR) and mean
difference (MD) with 95% confidence intervals (CI).